New treatments for IBS

Magnus Halland, Nicholas J. Talley

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

IBS is a common disorder that affects approximately 5-20% of the populations of Western countries; the main symptoms are abdominal pain and erratic, altered bowel habits, often accompanied by bloating. Despite an array of available pharmacological and nonpharmacological treatments aimed at a wide variety of gastrointestinal and brain targets, many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development of new molecules for pharmacological therapies to testing the utility of internet technology to facilitate widespread delivery of efficacious behavioural therapy. This Review discusses the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches. We have included estimates of the number needed to treat and the number needed to harm for selected treatments. Emerging and potential future treatments are included, with the data supporting an optimistic view about the future of IBS therapeutics. The ability to optimize therapy by individualizing management whilst also avoiding harm remains the key to achieving the best possible outcomes with currently available therapeutics.

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalNature Reviews Gastroenterology and Hepatology
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Therapeutics
Pharmacology
Numbers Needed To Treat
Aptitude
Internet
Abdominal Pain
Habits
Technology
Costs and Cost Analysis
Brain
Research
Population

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

New treatments for IBS. / Halland, Magnus; Talley, Nicholas J.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 10, No. 1, 01.01.2013, p. 13-23.

Research output: Contribution to journalReview article

Halland, Magnus ; Talley, Nicholas J. / New treatments for IBS. In: Nature Reviews Gastroenterology and Hepatology. 2013 ; Vol. 10, No. 1. pp. 13-23.
@article{33e04329b5df4657ac0b2f4c571058a3,
title = "New treatments for IBS",
abstract = "IBS is a common disorder that affects approximately 5-20{\%} of the populations of Western countries; the main symptoms are abdominal pain and erratic, altered bowel habits, often accompanied by bloating. Despite an array of available pharmacological and nonpharmacological treatments aimed at a wide variety of gastrointestinal and brain targets, many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development of new molecules for pharmacological therapies to testing the utility of internet technology to facilitate widespread delivery of efficacious behavioural therapy. This Review discusses the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches. We have included estimates of the number needed to treat and the number needed to harm for selected treatments. Emerging and potential future treatments are included, with the data supporting an optimistic view about the future of IBS therapeutics. The ability to optimize therapy by individualizing management whilst also avoiding harm remains the key to achieving the best possible outcomes with currently available therapeutics.",
author = "Magnus Halland and Talley, {Nicholas J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/nrgastro.2012.207",
language = "English (US)",
volume = "10",
pages = "13--23",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - New treatments for IBS

AU - Halland, Magnus

AU - Talley, Nicholas J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - IBS is a common disorder that affects approximately 5-20% of the populations of Western countries; the main symptoms are abdominal pain and erratic, altered bowel habits, often accompanied by bloating. Despite an array of available pharmacological and nonpharmacological treatments aimed at a wide variety of gastrointestinal and brain targets, many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development of new molecules for pharmacological therapies to testing the utility of internet technology to facilitate widespread delivery of efficacious behavioural therapy. This Review discusses the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches. We have included estimates of the number needed to treat and the number needed to harm for selected treatments. Emerging and potential future treatments are included, with the data supporting an optimistic view about the future of IBS therapeutics. The ability to optimize therapy by individualizing management whilst also avoiding harm remains the key to achieving the best possible outcomes with currently available therapeutics.

AB - IBS is a common disorder that affects approximately 5-20% of the populations of Western countries; the main symptoms are abdominal pain and erratic, altered bowel habits, often accompanied by bloating. Despite an array of available pharmacological and nonpharmacological treatments aimed at a wide variety of gastrointestinal and brain targets, many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development of new molecules for pharmacological therapies to testing the utility of internet technology to facilitate widespread delivery of efficacious behavioural therapy. This Review discusses the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches. We have included estimates of the number needed to treat and the number needed to harm for selected treatments. Emerging and potential future treatments are included, with the data supporting an optimistic view about the future of IBS therapeutics. The ability to optimize therapy by individualizing management whilst also avoiding harm remains the key to achieving the best possible outcomes with currently available therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84871964134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871964134&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2012.207

DO - 10.1038/nrgastro.2012.207

M3 - Review article

C2 - 23147658

AN - SCOPUS:84871964134

VL - 10

SP - 13

EP - 23

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 1

ER -